[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 2 sources · 20 days · First seen · Last updated

Regeneron and Sanofi Q2 2026 financial performance

Overview

In the second quarter of 2026, both Regeneron Pharmaceuticals and Sanofi reported strong financial growth, largely attributed to the performance of the immunology drug Dupixent.

Regeneron reported revenue of $4.29 billion, exceeding Wall Street expectations, with Dupixent generating $6.0 billion in global net sales. The company also noted it had fully repaid the Sanofi Development Balance.

Sanofi reported a 17.8 percent year-on-year revenue increase to 116 billion euros, with Dupixent contributing 52 billion euros. While experiencing growth, Sanofi announced it had discontinued four major drug development projects as part of a strategic review of its R&D activities.

Entities

Sanofi · Dupixent · Eylea · Mike Sumbs · Larry F. Mazza

Timeline

  1. 28 days ago

    [BUSINESS] 2 sources
    Sanofi reports strong Q2 2026 revenue growth driven by Dupixent

    Sanofi reported a 17.8% revenue increase to 116 billion euros in Q2 2026, driven by Dupixent sales, despite discontinuing several R&D projects.

  2. about 2 months ago

    [BUSINESS] 7 sources
    Regeneron Pharmaceuticals Q2 2026 earnings surpass estimates, driven by Dupixent sales

    Regeneron beat Q2 2026 forecasts with $4.29 B revenue, $14.29 EPS, Dupixent sales up 38 % to $6 B, and high‑dose Eylea U.S. sales up 52 %, while fully repaying its Sanofi balance.

Sources

ad-hoc-news.de · it-boltwise.de